Nearly half of eosinophilic esophagitis patients fail first-line therapy, and that treatment gap is now the target Amgen and AstraZeneca are aiming at. Top-line results from the Phase 3 CROSSING trial show tezepelumab hit both co-primary endpoints, histologic remission and meaningful reduction in dysphagia frequency and severity, at week 24, with those gains holding through week 52. That durability matters enormously in a condition affecting an estimated 472,000 people in the United States whose prevalence has risen five-fold since 2009, and where the daily calculus of eating carries genuine physical and emotional risk.
What distinguishes the CROSSING data is the dual-endpoint architecture. Histologic remission addresses the underlying eosinophilic inflammation; the Dysphagia Symptom Questionnaire captures what patients actually feel. Regulators and payers have grown skeptical of biomarker wins that don’t move patient-reported outcomes, so clearing both co-primary measures, plus all key secondary endpoints, closes that objection before it opens. The CROSSING population was on maintenance therapy and still uncontrolled, making these the patients most likely to attract payer scrutiny and most likely to need a differentiated mechanism. Tezepelumab blocks thymic stromal lymphopoietin upstream of the entire inflammatory cascade, which is a different point of intervention from IL-4/IL-13 inhibition, the mechanism already approved in this space.
The strategic read here is about label breadth, not just EoE alone. Tezepelumab earned its severe asthma approval in December 2021 and its chronic rhinosinusitis with nasal polyps indication in October 2025. A positive EoE filing would give tezepelumab a foothold across three distinct epithelial-driven inflammatory diseases, each with a partially overlapping patient population and each offering cross-label reinforcement for the same prescriber base. That kind of multi-indication depth changes commercial conversations with health systems from transactional to foundational.
Full data go to regulators and a medical meeting, so the submission timeline is the number to track. Amgen and AstraZeneca have not disclosed when they plan to file, and that gap between top-line readout and actual regulatory package determines whether EoE becomes a 2027 label addition or slips into 2028. Watch the date of the scientific presentation for signal on how clean and complete the dataset actually is.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
